| Literature DB >> 29996626 |
Yousry A Hawash1,2, Khadiga A Ismail1,3, Maha M Abdel-Wahab4, Mahmoud Khalifa5.
Abstract
Cutaneous leishmaniasis (CL) has been one of the most common parasitic diseases in Saudi Arabia. This study exhibits the clinical features, diagnosis, cytokine profile and treatment of CL patients in Al-Taif province. Ninety CL suspects at a tertiary care general hospital were enrolled in one-year study. Patients were interviewed, clinically-examined, and subjected to laboratory tests: skin scraping smear microscopy, OligoC-TesT commercial PCR (Coris BioConcept) and kinetoplast DNA (kDNA) PCR for Leishmania diagnosis. Interferon-gamma (RayBio; Human IFN-γ) and nitric oxide (NO) levels in patients' sera were evaluated before treatment with sodium stibogluconate (pentostam) with 20-day intramuscular drug regimen. Positive rates of microscopy, commercial PCR and kDNA PCR were 74.4%, 95.5% and 100%, respectively. Patients came to hospital mostly in winter (45.0%). CL was frequently exhibited in Saudi patients (78.8%), male gender (70.7%), age <20 years (50.0%), rural-dwellers (75.5%) and patients with travel history (86.6%). Lesion was mostly single ulcer (93.3%), occurred in the face (67.7%). Upon pentostam treatment, 85.1% of ulcers showed rapid healing signs. Levels of IFN-γ and NO were significantly higher in the healing than the non-healing cases (P<0.001). The kDNA PCR proved more sensitive than microscopy and OligoC-TesT commercial PCR. Our results open perspectives for IFN-γ use as a biomarker predicting treatment response.Entities:
Keywords: PCR diagnosis; clinical feature; cytokine profile; Cutaneous leishmaniasis
Mesh:
Substances:
Year: 2018 PMID: 29996626 PMCID: PMC6046557 DOI: 10.3347/kjp.2018.56.3.229
Source DB: PubMed Journal: Korean J Parasitol ISSN: 0023-4001 Impact factor: 1.341
Fig. 1Map of Al-Taif region in Saudi Arabia.
Fig. 2A month-wise distribution of 90 leishmanial cases enrolled in this study.
Demographic features of 90 CL suspects by age group
| Variable (No.) | Number of age group (%) | ||||
|---|---|---|---|---|---|
|
| |||||
| 5–19 yr | 20–39 yr | 40–59 yr | ≥60 yr | ||
| Gender | |||||
| Male (70) | 39 (43.3) | 10 (11.1) | 12 (13.3) | 9 (10) | 0.090533 |
| Female (20) | 6 (6.6) | 2 (2.2) | 8 (8.8) | 4 (4.4) | |
|
| |||||
| Residence | |||||
| Rural (68) | 37 (41.1) | 10 (11.1) | 12 (13.3) | 9 (10) | 0.22345 |
| Urban (22) | 8 (8.8) | 2 (2.2) | 8 (8.8) | 4 (4.4) | |
|
| |||||
| Nationality | |||||
| Saudi (71) | 42 (46.6) | 9 (10) | 9 (10) | 11 (12.2) | 0.000187 |
| Non-Saudi (19) | 3 (3.3) | 3 (3.3) | 11 (12.2) | 2 (2.2) | |
|
| |||||
| Travel history | |||||
| Yes (78) | 35 (38.8) | 11 (12.2) | 19 (21.1) | 13 (14.4) | 0.21331 |
| No (12) | 10 (11.1) | 1 (1.1) | 1 (1.1) | 0 (0.0) | |
|
| |||||
| Animals around house | |||||
| Yes (62) | 36 (40) | 7 (7.7) | 9 (10) | 10 (11.1) | 0.030195 |
| No (28) | 9 (10) | 5 (5.5) | 11 (12.2) | 3 (3.3) | |
Highly significant (P<0.001);
Significant (P<0.05).
Clinical features of CL active skin lesions by age group
| Lesion (patient no.) | Case number (%) of age group | ||||
|---|---|---|---|---|---|
|
| |||||
| 5–19 yr | 20–39 yr | 40–59 yr | ≥ 60 yr | ||
| Type | |||||
| Nodular (5) | 2 (2.2) | 1 (1.1) | 2 (2.2) | 0 (0.0) | 0.851897 |
| Ulcerative (85) | 43 (47.7) | 11 (12.2) | 18 (20) | 13 (14.4) | |
|
| |||||
| Ulcer | |||||
| Wet (12) | 5 (5.5) | 3 (3.3) | 3 (3.3) | 1 (1.1) | 0.506986 |
| Dry (73) | 38 (42.2) | 8 (8.8) | 15 (16.6) | 12 (13.3) | |
|
| |||||
| Duration | |||||
| <6 months (77) | 39 (43.3) | 9 (9.9) | 19 (21.1) | 10 (11.1) | 0.568424 |
| 6–12 months (9) | 5 (5.5) | 2 (2.2) | 1 (1.1) | 1 (1.1) | |
| >12 months (4) | 1 (1.1) | 1 (1.1) | 0 (0.0) | 2 (2.2) | |
|
| |||||
| Location | |||||
| Face (61) | 38 (42.2) | 6 (6.6) | 8 (8.8) | 9 (9.9) | 0 .000273 |
| Upper limbs (15) | 4 (4.4) | 5 (5.5) | 3 (3.3) | 3 (3.3) | |
| Lower limbs (14) | 3 (3.3) | 1 (1.1) | 9 (9.9) | 1 (1.1) | |
|
| |||||
| Number | |||||
| Single (84) | 43 (47.7) | 11 (12.2) | 19 (21.1) | 11 (12.2) | 0.722736 |
| Double (4) | 1 (1.1) | 1 (1.1) | 1 (1.1) | 1 (1.1) | |
| Multiple (2) | 1 (1.1) | 0 (0.0) | 0 (0.0) | 1 (1.1) | |
|
| |||||
| Surface area | |||||
| 1–5 cm (35) | 16 (17.7) | 4 (4.4) | 7 (7.7) | 8 (8.8) | 0.224655 |
| 5–10 cm (54) | 29 (32.2) | 8 (8.8) | 13 (14.4) | 4 (4.4) | |
| >10 cm (1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.1) | |
Highly significant (P<0.001).
Fig. 3An ethidium bromide-stained 1.5% agarose gel of kDNA semi-nested PCR. Lane 1, negative sample; lanes 2–5, amplification product (≈120 bp) of Leishmania spp. M, 100 bp DNA marker.
Serum concentration of interferon-gamma (IFN-γ) and nitric oxide (NO) in healing and non-healing leishmanial groups before pentostan® treatment
| Cytokine | Treatment groups | Statistical test | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
| Healing | Non-healing | Mann-Whitney U | Sig (2-tailed) | 95%CI | |||||
| Percentile | Median | 25 | 75 | Median | 25 | 75 | |||
|
| |||||||||
| IFN-γ (pg/ml) | 2,202.5 | 2,135.6 | 2,375.9 | 194.3 | 158.4 | 291.8 | 8.000 | 0.000 | 0-030 |
|
| |||||||||
| NO (μmol/L) | 38.2 | 31.8 | 55.1 | 6.2 | 4.8 | 8.7 | 6.000 | 0.000 | 0-030 |
Healing group, patients displayed rapid clinical cure after pentostan® treatment (n=34); Non-healing group, patients did not display clinical cure signs for pentostan® treatment (n=13); Sig (2-tailed), 2-tailed P-value;
Highly significant; CI, confidence interval.